# Lunit medical AI business developments

> Live situation record from CLSTR: https://clstr.news/situations/lunit-medical-ai-business-developments
> Updated: 2026-09-17T18:00:18.000Z. Sources: 4. Developments: 2.

Medical AI company Lunit has expanded its research and industry standing through new technical collaborations and international recognition.

In September 2026, Lunit announced a research partnership with 10x Genomics to discover biomarkers for predicting cancer treatment responses. The collaboration seeks to integrate 10x Genomics’ gene analysis with Lunit’s AI pathology platform, ‘Lunit SCOPE IO’, to identify how molecular data manifests in pathological images, specifically regarding immuno-oncology and antibody-drug conjugates.

During the same period, Lunit was named one of the ‘World’s Top HealthTech Companies 2026’ by TIME magazine and Statista within the ‘Diagnostics’ category. The company’s AI imaging solution, ‘Lunit INSIGHT’, is used by over 10,000 medical institutions globally, with overseas revenue representing 95% of its total sales as of the second quarter of the previous year.

## Timeline

### 2026-09-17: Lunit named one of TIME’s top global healthtech companies

Medical AI company Lunit has been named one of TIME’s ‘World’s Top HealthTech Companies 2026’ in the diagnostics category, highlighting its global reach across 10,000 medical institutions.

2 sources. https://clstr.news/cluster/lunit-named-one-of-times-top-global-healthtech-companies

### 2026-09-11: Lunit and 10x Genomics partner to discover precision medicine biomarkers

Lunit and 10x Genomics are collaborating to discover precision medicine biomarkers by combining AI pathology analysis with spatial biology to predict cancer treatment responses.

4 sources. https://clstr.news/cluster/lunit-and-10x-genomics-partner-to-discover-precision-medicine-biomarkers

---
Cite as: Lunit medical AI business developments. CLSTR, https://clstr.news/situations/lunit-medical-ai-business-developments